Abstract
AbstractFrequent monitoring of serum alanine aminotransferase (ALT) activity is essential to prevent drug-induced liver injury (DILI). Current ALT assays are restricted to centralized clinical laboratories, making frequent patient monitoring logistically difficult. To address this, we demonstrated the capability of commercial foundry manufactured silicon nanowire field effect transistor (SiNW-FET) biosensors in a form factor that enables frequent near-patient monitoring. Here, we designed an ALT assay, by coupling the ALT-catalyzed production of pyruvate to the reduction of ferricyanide, enabling both spectrophotometric and electrical measurement of ALT activity. The two methods yield comparable ALT activity detection across a dynamic range wide enough to monitor patients at risk for DILI. This study demonstrates kinetic activity measurement of an endogenous enzyme using uncoupled SiNW-FETs, and commercial manufacturing of SiNW-FET sensor arrays for use in a portable biosensor platform.
Publisher
Springer Science and Business Media LLC
Reference62 articles.
1. Chen, M. et al. FDA-approved drug labeling for the study of drug-induced liver injury. Drug Discov. Today 16, 697–703 (2011).
2. FDA, U. Guidance for Industry Drug-Induced Liver Injury: Premarketing Clinical Evaluation. U.S. Food and Drug Administration. Silver Spring, MD. (2009).
3. Avigan, M. I. DILI and drug development: a regulatory perspective. Semin. Liver Dis. 34, 215–226 (2014).
4. Zimmerman, H. J. Hepatotoxicity: The Adverse Effects of Drugs and Other Chemicals on the Liver (Lippincott Williams & Wilkins, 1999).
5. Hoofnagle, J. H. & Björnsson, E. S. Drug-induced liver injury—types and phenotypes. New Engl. J. Med. 381, 264–273 (2019).
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献